8045 Lamon Avenue
52 articles with Exicure, Inc.
Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced that its CFO, David Snyder, will give a company presentation on Tuesday, April 2, 2019 at 9:30 am ET at the Spring Investor Summit.
Completed Phase 1 clinical trials of two drugs and began public trading
Exicure, Inc., a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced that it has dosed the first patient in its multicenter, open-label, Phase 1b/2 study of AST-008 combined with pembrolizumab.
Exicure, Inc. announced that its CEO, Dr. David Giljohann, will present a corporate update at the 12th Annual European Life Sciences CEO Forum being held February 25-26, 2019 at the Hilton Zurich Airport Hotel in Zurich, Switzerland.
Exicure Announces License and Development Agreement with Dermelix Biotherapeutics in Rare Genetic Skin Diseases
Agreement Leverages Recent Clinical Success of Exicure in Dermatology
Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced that its CEO, Dr. David Giljohann, will present at SMi’s RNA Therapeutics 2019 Conference being held February 20-21, 2019 at the Copthorne Tara Hotel in London, UK.
Exicure, Inc. announced that its CEO, Dr. David Giljohann, will present a corporate update on Monday, February 11, 2019 at 11:15 am EST at the BIO CEO & Investor Conference.
Exicure, Inc. today announced four of the clinical trial sites for the Company’s Phase 1b/2 trial of AST-008.
Exicure, Inc. announced today that its CEO, Dr. David Giljohann, will present at the Immuno-Oncology 360° Conference (IO360°) being held February 6-8, 2019 at the Crowne Plaza Times Square in New York City.
Exicure, Inc. announced today that its CEO, Dr. David Giljohann, will present a corporate update on Tuesday, January 8, 2019 from 2:30 pm to 3:00 pm PT at the Biotech Showcase 2019.
Exicure, Inc. (OTCQB:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today top-line results from a Phase 1 clinical trial evaluating XCUR17 in patients with mild-to-moderate chronic plaque psoriasis. XCUR17 is an SNA drug targeted to mRNA encoding interleukin 17 receptor alpha, or IL-17RA. IL-17RA is a key protein that propagates inflammation.
Exicure, Inc. announced today plans to attend two investor conferences and two scientific conferences in November 2018.
Announced launch of a Phase1b/2 trial for AST-008, Exicure’s TLR9 agonist drug candidate designed for immuno-oncology applications.
Exicure Presents First Data Demonstrating Both Oral Delivery and Liver Delivery of Spherical Nucleic Acid Constructs in Animal Models
Two posters presented at the 14th Annual Meeting of the Oligonucleotide Therapeutics Society in Seattle, Washington
Data on Exicure’s TLR9 Agonist Spherical Nucleic Acid (SNA™) Construct Presented at the 4th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
Exicure technology shows effective antitumor activity in mouse tumor models
Exicure, Inc. announced today that Dr. David Giljohann, Chief Executive Officer of Exicure, will present at the Ladenburg Thalmann 2018 Healthcare Conference and Leerink Partners Roundtable Series: Rare Disease & Oncology.
First in human results demonstrate potent immune system activation with no serious adverse events or dose limiting toxicity
Exicure, Inc. announced today it expects to close a private placement offering of its common stock at a per share price of $4.50 and aggregate gross proceeds of approximately $22 million before fees and expenses.
Exicure, Inc. reported financial results for the second quarter ended June 30, 2018, and provided an update on corporate progress.
Exicure, Inc. to Present at the 2018 JMP Securities Life Sciences Conference on June 21st at 11:00 a.m. EDT
A live webcast of the presentation will be available on the Events & Presentations section of Exicure's website, where it will also be archived and available for replay following the presentation for 30 days.